Study of A-337 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug, A-337, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if A-337 is safe and effective, and to find the right dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have an advanced solid tumor that has not responded to standard treatments or you cannot have standard treatments.
- You have at least one tumor that can be measured on a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted drug called ACR-2316 for people with specific advanced solid tumors that have already been treated but are no longer responding. It aims to see how well the drug works and how safe it is, while looking for a tumor that has certain markers (like a protein or genetic change) that may make the drug more effective.
This phase 1 trial tests a new drug called AK137, which is designed to help your immune system better attack cancer cells. It is for people with advanced tumors that have not been helped by standard therapies. The goal is to find out if AK137 is safe and effective.
This trial tests a new drug called CMAB017 for people with advanced solid tumors who have run out of standard options. The goal is to find a safe dose and see how well it is tolerated.
This Phase 1 trial tests how safe AM-928 is when given through an IV infusion to people with advanced solid cancers that can’t be removed by surgery and have stopped responding to standard treatments. It may help doctors learn the safest dose and whether the drug causes side effects worth watching.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This trial tests an experimental drug called SM2275 for people with advanced solid tumors that have certain markers (EGFR and PD-L1) and have stopped responding to standard treatments. The drug is given by injection and may offer a new option when other treatments have not worked.
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.